Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

drug licensing

This page shows the latest drug licensing news and features for those working in and with pharma, biotech and healthcare.

Merck enters agreement with Hanmi for investigational NASH drug

Merck enters agreement with Hanmi for investigational NASH drug

NGM313 is an antibody targeting the beta-Klotho/FGFR1c receptor complex that could represent a new a completely new drug class for NASH and diabetes. ... The drug works by activating FGFR1c signalling, a pathway that appears to have a key role in

Latest news

More from news
Approximately 2 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    first launched on the world drug market than major companies (those with R&D spend of US$2bn). ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the

  • ‘Flexible working’: fashionable buzzword or fundamental business operation? ‘Flexible working’: fashionable buzzword or fundamental business operation?

    Externally, there are the usual issues: downward pressure on hourly rates, reduced client budgets, environmental pressures on new drug development and licensing/reimbursement.

  • Charting a course for expansion Charting a course for expansion

    a key licensing agreement and the not inconsequential matter of a management reshuffle. ... Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug

  • Pharma deals during January 2013 Pharma deals during January 2013

    Out licensing WW rights to RN 307 antibody (binds to calcitonin related peptide) phase II ready. ... 18-MC (18-methoxycoronaridine) as a treatment for drug addiction, obesity and compulsive behaviour.

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    However, Sanofi has since discontinued its development. The company announced in May 2011 that the drug is available for licensing. ... The drug is also in phase III development for the acute treatment of VTE.

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    Prior to this, she has served as senior vice president, head of global business development at Teva Pharmaceuticals, where she led and executed multiple business development transactions ranging from licensing to ... acquisition of drug candidates,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....

Quick links